Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.

The synthesis and evaluation of benzetimide derivatives showing potent CXCR3 antagonism are described. Optimization of the screening hits led to the identification of more potent CXCR3 antagonists devoid of anti-cholinergic activity and identification of the key pharmacophore moieties of the series.

[1]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[2]  Kenji Suzuki,et al.  Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival , 2002, European journal of immunology.

[3]  D. Owen,et al.  Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[4]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[5]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[6]  L. Fabbri,et al.  Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[7]  P. Loetscher,et al.  Lymphocyte‐specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization , 1998, European journal of immunology.

[8]  I. D. de Esch,et al.  Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[9]  Helen L Birch,et al.  Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives. , 2008, Bioorganic & medicinal chemistry letters.

[10]  J. Flier,et al.  The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. , 1999, The Journal of investigative dermatology.

[11]  R. Leurs,et al.  Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). , 1999, The Journal of investigative dermatology.

[12]  T. Junt,et al.  β cells are responsible for CXCR3-mediated T-cell infiltration in insulitis , 2002, Nature Medicine.

[13]  M. Burdick,et al.  Role of CXCL9/CXCR3 Chemokine Biology during Pathogenesis of Acute Lung Allograft Rejection 1 , 2003, The Journal of Immunology.

[14]  Feng Xu,et al.  Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. , 2007, Bioorganic & medicinal chemistry letters.

[15]  R. Ravid,et al.  Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system , 2002, Journal of Neuroimmunology.

[16]  B. Lemon,et al.  Design and optimization of imidazole derivatives as potent CXCR3 antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[17]  J. Malin,et al.  Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing–remitting multiple sclerosis , 2002, Journal of Neuroimmunology.

[18]  B. Lemon,et al.  Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists. , 2008, Bioorganic & medicinal chemistry letters.